GLP-1 Drugs in Kidney Transplant Patients: Systematic Review Finds Limited but Encouraging Safety Data | Research

The takeaway

A meta-analysis of retrospective studies suggests GLP-1 RAs may be safe in kidney transplant recipients with type 2 diabetes, but evidence remains limited.

Limited retrospective data
No RCTs yet available for GLP-1 RAs in kidney transplant patients

What the researchers found

Limited retrospective evidence suggests GLP-1 RAs may be safe regarding mortality, MACE, and MAKE in kidney transplant recipients with type 2 diabetes.

Why it matters

Kidney transplant patients with diabetes need effective glucose and weight management but face unique risks. Establishing GLP-1 RA safety in this population could expand treatment options.

How the study worked

Systematic review and meta-analysis of retrospective cohort studies examining GLP-1 RA outcomes in adult kidney transplant recipients.

What this study cannot tell us

Based entirely on retrospective cohort data — no RCTs available; small pooled sample sizes limit statistical power; transplant-specific confounders difficult to control.

How to read the evidence

Meta-analysis of retrospective cohorts — provides the best available synthesis but is limited by the observational nature and small size of included studies.

When this study was published

Published 2026. Reflects the early evidence base for this specific population.

The bigger picture

As GLP-1 RAs prove beneficial in general CKD populations, extending evidence to transplant recipients is a critical next step for comprehensive metabolic care.

Questions still open

Will prospective trials confirm GLP-1 RA safety in kidney transplant recipients?
Do GLP-1 RAs interact with immunosuppressive medications commonly used post-transplant?

Common questions

Can kidney transplant patients take GLP-1 medications?

Limited evidence suggests GLP-1 drugs may be safe in kidney transplant patients, but the data comes only from small retrospective studies. Prospective trials are needed before firm recommendations can be made.

Why is evidence so limited for this group?

Kidney transplant patients are typically excluded from major GLP-1 RA clinical trials due to their complex medication regimens and unique health risks, leaving only observational data available.

Read the original research

GLP-1 receptor agonists in kidney transplant recipients with type 2 diabetes mellitus: a systematic review and meta-analysis on mortality and major adverse kidney events.

Journal of diabetes and metabolic disorders, 25(1), 29

View on PubMed ↗Publisher’s paper ↗

Citation

Aliyeva, Turkan; Natche, Julia; Jiakponna, Enyinnaya Calistus; Ahmad, Feras; Eze, Belinda; Nawaz, Usama Hassan; El-Amri, Imane; Shrestha, Sheelu. (2026). GLP-1 receptor agonists in kidney transplant recipients with type 2 diabetes mellitus: a systematic review and meta-analysis on mortality and major adverse kidney events.. Journal of diabetes and metabolic disorders, 25(1), 29. https://doi.org/10.1007/s40200-025-01801-7